Study seeks clues on antibody formation in rare bleeding disorder
NCT ID NCT04595617
First seen May 24, 2026 · Last updated May 24, 2026
Summary
This study looked at 28 people with Glanzmann thrombasthenia, a rare bleeding disorder, to find out why some develop harmful antibodies after blood transfusions or pregnancy. Researchers checked genetic, treatment, and lifestyle factors linked to antibody formation. The goal is to better understand risks and improve future care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLANZMANN THROMBASTHENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Bordeaux - Hôpital Haut-Lévêque
Bordeaux, France
-
CHU Bordeaux - Hôpital Pellegrin
Bordeaux, France
-
CHU Nîmes
Nîmes, France
-
CHU Strasbourg
Strasbourg, France
-
CHU Toulouse
Toulouse, France
-
Hôpital Bicêtre, APHP
Le Kremlin-Bicêtre, France
-
Hôpital la Timone, APHM
Marseille, France
Conditions
Explore the condition pages connected to this study.